<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046044</url>
  </required_header>
  <id_info>
    <org_study_id>KK&amp;DU-Iva-Dig2014</org_study_id>
    <nct_id>NCT02046044</nct_id>
  </id_info>
  <brief_title>Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction</brief_title>
  <acronym>DIVA-REF</acronym>
  <official_title>Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kocaeli University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kocaeli University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: Comparing the effect of digoxin and ivabradine in chronic heart failure
      patients with a left ventricular ejection of 35% or lower and sinus rhythm with heart rate 70
      beats per minute or higher, and who are taking maximal dose of a beta blocker if tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Selected patients have chronic heart failure with left ventricular systolic dysfunction and
      sinus rhythm. They take optimal medical therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac function and functional status and biochemical parameters</measure>
    <time_frame>After 6 months</time_frame>
    <description>Cardiac function (echocardiography): Systolic function (left ventricular ejection fraction) and diastolic function (Doppler E/A ratio, tissue Doppler e/e1 ratio, Doppler deceleration time of the E wave, left atrium volume index) Maximal oxygen consumption will be evaluated with cardiopulmonary exercise testing Changes in proBNP level (serum value) after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Death from cardiovascular reasons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for worsening heart failure</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate and blood pressure</measure>
    <time_frame>After 6 months</time_frame>
    <description>Changes in heart rate and blood pressure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization for a cardiovascular reason</measure>
    <time_frame>Up to 6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <arm_group_label>Digoxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Inclusion Criteria:

               -  Left ventricular ejection fraction of 35% or lower (Ischaemic or non-ischaemic
                  etiology)

               -  Sinus rhythm with heart rate of 70 beats per minute or higher

               -  Symptomatic heart failure with functional capacity of New York Heart Association
                  class II, III, IV

          2. Exclusion Criteria:

               -  Chronic renal failure with glomerular filtration rate &lt;30 ml/min

               -  Atrial fibrillation

               -  Pace maker rhythm

               -  Advanced stage chronic obstructive lung disease

               -  Comorbidity with expected survival below 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kurtulus Karauzum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kurtulus Karauzum, MD</last_name>
    <phone>90 555 726 87 90</phone>
    <email>kurtuluskarauzum@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kocaeli University</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurtulus Karauzum, MD</last_name>
      <phone>90 555 726 87 90</phone>
      <email>kurtuluskarauzum@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kocaeli University</investigator_affiliation>
    <investigator_full_name>Kurtulus Karauzum</investigator_full_name>
    <investigator_title>Kurtulus Karauzum</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Digoxin</keyword>
  <keyword>Ivabradine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

